FAST PLATE
LIVE

Serial Number

88313174

Owner

Essenlix Corporation

Attorney

Xiongying Tu

Filing Date

Feb 23, 2019

Add to watchlist:

No watchlists yet
View on USPTO

FAST PLATE Trademark

Serial Number: 88313174

FAST PLATE is a trademark filed by Essenlix Corporation on February 23, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Essenlix Corporation (148 trademarks)

7 Foulet Dr
Princeton, CA 08540

Entity Type: 03

Trademark Details

Filing Date

February 23, 2019

Registration Date

Not Registered

Goods & Services

Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents and assays for testing cells, proteins, small molecules, nucleotides, and nucleic acids; Medical diagnostic reagents; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancers, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Diagnostic biomarker reagents for medical purposes; all of the aforesaid not in the nature of diagnostic immunological assay tests used for testing food safety and kits containing medical reagent solutions which are used sequentially in the thawing of cryopreserved human blastocysts; all of the foregoing employing the staining of biological samples

Medical diagnostic apparatus for testing cells, tissue, biomolecules, proteins, small molecules, and nucleotides; Medical devices for obtaining bodily fluid samples; Medical diagnostic instruments for the analysis of bodily fluids; Medical apparatus for diagnostic use, namely, medical apparatus for diagnostic testing of health conditions, diseases, or abnormalities, namely, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, genetic diseases, and endocrine diseases, and other tissue-based diagnostic testing, cytology, and cell based testing; Medical apparatus, devices, and instruments for wellness testing, health condition testing, and healthcare testing, namely, point-of-care diagnostic devices, at-home diagnostic devices, and portable health monitoring devices that detect health conditions and diseases in the nature of cancers, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases and genetic diseases; Medical apparatus, devices, and instruments for the detection and identification of nucleic acids, namely, DNA and RNA in a sample, in the nature of apparatus for DNA and RNA testing for medical purposes; Biological and chemical testing kits for personal wellness in the nature of diagnostic test kits consisting primarily of medical diagnostic reagents and assays for the detection of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Medical diagnostic instruments for the analysis of body fluids in the nature of biological and chemical test kits for the detection and identification of nucleic acids, namely DNA and RNA in a sample; all of the aforesaid not in the nature of diagnostic immunological assay tests used for testing food safety and kits containing medical reagent solutions which are used sequentially in the thawing of cryopreserved human blastocysts; all of the foregoing employing the staining of biological samples

Medical services; Medical assistance; Medical consultations; Medical counseling; Medical information; Healthcare services in the field of digital healthcare services; Diagnostic services, namely, medical testing for diagnostic purposes; Wellness services, namely, providing wellness information; Medical services, medical assistance, medical consultations, medical counseling, medical information, healthcare testing, diagnostic testing, and wellness services, all in the fields of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, genetic diseases, and other tissue-based diagnostic testing, cytology, and cell-based testing; Medical testing services for the detection and identification of cells, proteins, small molecules, and nucleic acids in a sample; all of the aforesaid not in the nature of physical therapy evaluation, identification, and management of movement dysfunction to restore, maintain, and promote optimal physical function preventing the onset, symptoms and progression of impairments, functional limitations, and disabilities resulting from disease, disorders, conditions, or injuries, and not in the nature of medical evaluation and medical screening services relating to diagnosing ADD and ADHD, medical treatment and cognitive therapy for ADD and ADHD, and health, medical and psychological counseling and treatment services in the field of ADD and ADHD; all of the foregoing employing the staining of biological samples

Assays for research purposes; Biological and chemical reagents used for non-medical research or laboratory purposes, namely, in vitro and in vivo scientific use, the testing of bodily fluids, and the detecting and analyzing of cells, proteins, small molecules, and nucleotides; Biological and chemical test kits comprised of biological, chemical, and diagnostic reagents for the detection and identification of nucleic acids, namely, DNA and RNA in a sample, for laboratory or research use; all of the aforesaid not in the nature of diagnostic immunological assay tests used for testing food safety and kits containing medical reagent solutions which are used sequentially in the thawing of cryopreserved human blastocysts; all of the foregoing employing the staining of biological samples

Filing History

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 26, 2026 RCCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 3, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 3, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 3, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 3, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 3, 2026 COAR
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Nov 27, 2025 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 26, 2025 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 21, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Nov 20, 2024 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 16, 2024 RCSC
WITHDRAWAL OF ATTORNEY GRANTED
Oct 9, 2023 WOAG
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Oct 9, 2023 WOAR
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jun 11, 2023 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Dec 12, 2022 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jun 13, 2022 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 10, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 10, 2021 GNSL
SUSPENSION LETTER WRITTEN
Dec 10, 2021 CNSL
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Nov 2, 2021 RCCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 11, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 11, 2021 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Oct 11, 2021 ERSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 5, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 5, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 5, 2021 REAP
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 27, 2021 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Oct 27, 2020 RCSC
ASSIGNED TO EXAMINER
Jul 30, 2020 DOCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 27, 2020 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 25, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 25, 2019 GNSL
SUSPENSION LETTER WRITTEN
Oct 25, 2019 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 15, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 15, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 15, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 15, 2019 GNRN
NON-FINAL ACTION E-MAILED
Apr 15, 2019 GNRT
NON-FINAL ACTION WRITTEN
Apr 15, 2019 CNRT
ASSIGNED TO EXAMINER
Apr 8, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 15, 2019 NWOS
NEW APPLICATION ENTERED
Feb 27, 2019 NWAP